Young & Partners Chemical Financing: Reflections on 2023 and Outlook (March 2024)
Proprietary data and analysis of chemical financing trends in 2023 and the current outlook.
Biopharma Industry Business Review and Outlook (Pharmaceutical Executive, March 2024)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed the M&A, stock market and financing in 2023, and the outlook for 2024.
Biopharma Market Review and Outlook (Pharmaceutical Executive, October 2023)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed the M&A, stock market and financing in the first half, and the outlook for 2023.
Chem Financing to Remain Challenged (ICIS Chemical Business August 18 – August 24, 2023)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed Financings and the outlook for 2023.
Chemical M&A Activity Turns Up (ICIS Chemical Business August 11 – August 17, 2023)
Young & Partners shares proprietary analysis of the global disruptions and uncertainties that have suppressed M&A and the outlook for 2023.
Young & Partners Biotech Financing Review and Outlook (June 21, 2023)
Proprietary data and analysis of the first quarter of 2023 and the current outlook.
Young & Partners Chemical M&A Review and Outlook (June 5, 2023)
Proprietary data and analysis of the first quarter of 2023 and the current outlook.
Young & Partners Pharma M&A Review and Outlook (June 2, 2023)
Proprietary data and analysis of the first quarter of 2023 and the current outlook.
Young & Partners Biotech M&A Review and Outlook (June 2, 2023)
Proprietary data and analysis of the first quarter of 2023 and the current outlook.
Biopharma M&A: Year in Review, Ripples Ahead (Pharmaceutical Executive, March 2023)
Young & Partners shares analysis of the global disruptions and uncertainties that have affected Biopharma M&A and the outlook for 2023.